Business Context and Reporting Period
This Form 6-K filing by Hong Kong Pharma Digital Technology Holdings Limited (the "Company") covers the month of November 2025, with the report dated November 12, 2025. The filing primarily addresses corporate governance changes involving the resignation of two independent directors and the appointment of their successors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes and does not contain financial performance data.
Material Changes
The material changes reported in this filing are strictly related to the Board of Directors:
- Resignations: Ms. Raina Zou and Dr. King Yin Lai resigned as Independent Directors on November 6, 2025, for personal reasons. Both stated there was no disagreement with the Company regarding operations, policies, or practices.
- Appointments:
- Ms. Jingyan Wu: Appointed as Independent Director, Chairperson of the Audit Committee, and member of the Compensation and Nominating/Corporate Governance Committees. She brings over 20 years of accounting experience, including prior roles as CFO at EZGO Technologies Ltd. and Senior Internal Auditor at MSIG Holdings and Children's Place Inc.
- Mr. Yao Mike Zhou: Appointed as a member of the Audit Committee and Chairperson of the Compensation Committee to fill the vacancy left by Dr. Lai.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies were disclosed other than the standard indemnification agreement for the new director. The Company confirmed there are no reportable related party transactions involving the new appointee, Ms. Wu.
Key Facts for Investor Verification
- Verify the effective date of the board changes (November 6, 2025) and the interim nature of the appointments until the next annual general meeting.
- Confirm the annual compensation for the new director, Ms. Jingyan Wu, is set at US$25,000 payable quarterly in arrears.
- Note that the resignations were explicitly stated as being for personal reasons with no underlying disputes.
- Review Ms. Wu's background as a Certified Public Accountant with experience at U.S. public companies to assess audit committee oversight capabilities.